Form 4: BioCardia Director Simon Stertzer Buys Shares

BioCardia, Inc. Director Simon H. Stertzer acquired shares in the company through multiple transactions on June 22 and June 23, 2026.

Summary

• Director Simon H. Stertzer acquired a total of 109,200 shares of BioCardia, Inc. common stock across two transactions.
• On June 22, 2026, 70,200 shares were acquired at a weighted average price of $0.92 per share, with individual trades ranging from $0.90 to $0.97.
• On June 23, 2026, an additional 39,000 shares were acquired at a weighted average price of $1.00 per share, with individual trades ranging from $1.00 to $1.01.
• Following these transactions, Mr. Stertzer's direct beneficial ownership increased, and he also holds indirect beneficial ownership of additional shares through various trusts and LLCs.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to the director's acquisition of shares, indicating insider confidence, though the filing itself is purely transactional.

Positives

• Director Simon H. Stertzer has increased his direct beneficial ownership in BioCardia, Inc. by acquiring 109,200 shares.
• The acquisitions were made at prices below $1.01 per share, potentially indicating a belief in the company's undervaluation by a key insider.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by directors, can be interpreted as a positive signal of confidence in the company's future prospects, especially when occurring at relatively low price points.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive indicator of confidence in the company's value.
• The increase in direct beneficial ownership by a director could signal a commitment to the company's long-term strategy.

Key Dates

Recommendation

This filing reports an insider purchase, which is generally a positive signal. However, it is a Form 4 detailing transactions and does not provide new fundamental information about the company's performance or outlook. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor the stock while awaiting more comprehensive updates.

Keywords

BioCardia, BCDA, Insider Trading, Form 4, Director Transaction, Common Stock, Securities Ownership